Cardiovascular Biomarkers in Cardio-Oncology : Antineoplastic Drug Cardiotoxicity and Beyond
Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Biomolecules - 14(2024), 2 vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Attanasio, Umberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 27.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/biom14020199 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368874214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368874214 | ||
| 003 | DE-627 | ||
| 005 | 20240229164630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biom14020199 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368874214 | ||
| 035 | |a (NLM)38397436 | ||
| 035 | |a (PII)199 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Attanasio, Umberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Biomarkers in Cardio-Oncology |b Antineoplastic Drug Cardiotoxicity and Beyond |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cardiac dysfunction | |
| 650 | 4 | |a cardiotoxicity | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a natriuretic peptides | |
| 650 | 4 | |a omics science | |
| 650 | 4 | |a troponin | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Di Sarro, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Tricarico, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lisi, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Armentaro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Miceli, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Fioretti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Deidda, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Correale, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Novo, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Sciacqua, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Nodari, Savina |e verfasserin |4 aut | |
| 700 | 1 | |a Cadeddu, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Tocchetti, Carlo Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Palazzuoli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mercurio, Valentina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomolecules |d 2011 |g 14(2024), 2 vom: 07. Feb. |w (DE-627)NLM228347106 |x 2218-273X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biom14020199 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 07 |c 02 | ||